• Quantum BioPharma reported patient enrollment reached the halfway mark in an ongoing imaging study with Massachusetts General Hospital testing a PET technique to track demyelination in multiple sclerosis.
• Preliminary imaging results have already been generated, showing clear uptake in acute MS lesions with early indications it may also detect gray matter lesions.
• The study aims to validate the [18F]3F4AP tracer as a biomarker that could sharpen how disease progression and treatment response are measured in MS.
• Management framed the work as supportive of development plans for Lucid-MS, its PAD2-targeting candidate positioned to protect myelin and slow neurodegeneration.
• An FDA IND submission for a Phase 2 Lucid-MS trial was filed in March 2026, with the company targeting clinical and imaging endpoints.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Biopharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180300PRIMZONEFULLFEED9721881) on May 18, 2026, and is solely responsible for the information contained therein.